---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-020850"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:26:25.545257+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# COMPASS Pathways reports Q2 net loss of $21.0M, appoints Kabir Nath as CEO

## Summary
- Net loss for Q2 2022 was $21.0M ($0.50 loss per share) vs $17.5M ($0.44) in Q2 2021.
- Cash and cash equivalents of $207.2M at June 30, 2022, down from $273.2M at Dec 31, 2021.
- Kabir Nath appointed CEO; George Goldsmith remains Executive Chairman through Dec 2022.
- Phase 3 protocols for COMP360 in TRD submitted to FDA, under review; Phase 3 start expected Q4 2022.
- Phase 2 study of COMP360 in anorexia nervosa launched across four research sites in the UK and US.

## SEC filing metadata
- accession: 0001628280-22-020850
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000162828022020850/0001628280-22-020850-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000162828022020850/cmps-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-020850
- JSON: https://secwatch.observer/filing/0001628280-22-020850.json
- Plain text: https://secwatch.observer/filing/0001628280-22-020850.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.